DMAPT-DTCs-1,3-diaminopropane-DTCs-DMAPT dimethanesulfonate

Cat. No.: HY-182918: Data Sheet Handling Instructions
FAQs
Technical Support

DMAPT-DTCs-1,3-diaminopropane-DTCs-DMAPT dimethanesulfonate is an orally active prodrug of MMB-DTCs-1,3-diaminopropane-DTCs-MMB (HY-182917). DMAPT-DTCs-1,3-diaminopropane-DTCs-DMAPT dimethanesulfonate induces apoptosis, ferroptosis, and cuproptosis in lung cancer cells. DMAPT-DTCs-1,3-diaminopropane-DTCs-DMAPT dimethanesulfonate can be used in the research of lung cancer.

For research use only. We do not sell to patients.

DMAPT-DTCs-1,3-diaminopropane-DTCs-DMAPT dimethanesulfonate Chemical Structure

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

DMAPT-DTCs-1,3-diaminopropane-DTCs-DMAPT dimethanesulfonate (Compound 92) exhibits selective anti-proliferative activity against NCI-H820 lung adenocarcinoma cells (IC₅₀ = 0.86 μM) with reduced potency against normal 3T3 fibroblasts (IC₅₀ = 1.83 μM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

DMAPT-DTCs-1,3-diaminopropane-DTCs-DMAPT dimethanesulfonate (Compound 92) (20-50 mg/kg; i.p.; once every 2 days for a total of 19 days) exhibits potent anti-lung cancer activity in the NCI-H820 CDX model, reduces tumor volume and weight, and induces apoptosis, ferroptosis and cuproptosis^[1].
DMAPT-DTCs-1,3-diaminopropane-DTCs-DMAPT dimethanesulfonate (20-100 mg/kg; p.o., i.p.; once every 2 days; for 17 consecutive days) exhibits anti-lung cancer activity in lung adenocarcinoma PDX models by inducing apoptosis, ferroptosis and cuproptosis^[1].
DMAPT-DTCs-1,3-diaminopropane-DTCs-DMAPT dimethanesulfonate (20-500 mg/kg; oral administration, intraperitoneal injection; single dose) shows no obvious in vivo toxicity at oral doses up to 500 mg/kg and intraperitoneal doses up to 50 mg/kg, with only mild toxicity observed at an intraperitoneal dose of 100 mg/kg^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Balb/c mice (female, n=7 per group; subcutaneous inoculation of 5 × 10⁶ NCI-H820 cells)^[1]
Dosage:	20 mg/kg; 50 mg/kg
Administration:	i.p.; every 2 days; 19 days
Result:	Significantly reduced tumor volume and tumor weight compared to controls, without affecting mouse body weight. Decreased tumor tissue levels of anti-apoptotic protein Bcl-2, ferroptosis-related protein GPX4, and cuproptosis-related proteins FDX1 and DLAT significantly. Increased pro-apoptotic protein Bax significantly.

Animal Model:	Balb/c nude mice (n=6 per group; subcutaneous inoculation of 3−5 mm³ patient-derived lung adenocarcinoma tissue)^[1]
Dosage:	50 mg/kg (p.o.); 100 mg/kg (p.o.); 20 mg/kg (i.p.); 50 mg/kg (i.p.)
Administration:	p.o.; every 2 days; 17 days; i.p.; every 2 days; 17 days
Result:	Reduced tumor volume and tumor weight compared to controls at all tested doses, without affecting mouse body weight. Decreased tumor tissue levels of anti-apoptotic protein Bcl-2, ferroptosis-related protein GPX4, and cuproptosis-related proteins FDX1 and DLAT significantly. Increased pro-apoptotic protein Bax significantly. Showed superior efficacy via intraperitoneal administration compared to oral administration.

Molecular Weight

1001.39

Formula

C₄₁H₆₈N₄O₁₂S₆

SMILES

S=C(SC/C1=C/CC[C@]2(C)[C@@H](O2)[C@@H](OC([C@H]3CN(C)C)=O)[C@H]3CC1)NCCCNC(SC/C4=C/CC[C@]5(C)[C@@H](O5)[C@@H](OC([C@H]6CN(C)C)=O)[C@@H]6CC4)=S.O=S(C)(O)=O.O=S(C)(O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Bai Y, et al. Identification of Melampomagnolide B Derivatives as Triggers of Cuproptosis, Ferroptosis, and Apoptosis for Treatment of Lung Cancer. J Med Chem. 2026;69(7):8255-8284.